earnings
confidence high
sentiment neutral
materiality 0.65
Design Therapeutics Q1 net loss $13.3M; cash $371.2M; DT-216 Phase 1 underway
Design Therapeutics, Inc.
2023-Q1 EPS reported
-$0.24
- Net loss of $13.3M for Q1 2022; R&D expenses $8.8M, G&A $4.6M.
- Cash, cash equivalents and marketable securities of $371.2M as of March 31, 2022.
- DT-216 Phase 1 single-ascending dose trial in Friedreich ataxia patients; topline data expected H2 2022.
- DT-216 received FDA Fast Track designation for FA.
- Preclinical data for Fuchs endothelial corneal dystrophy GeneTAC molecules showed up to 99% reduction in toxic RNA foci.